Advertisement
Evotec, Novo Nordisk Roll Out LAB EN To Accelerate Translation In Cardiometabolic Diseases
(RTTNews) - Evotec SE (EVO, EVOTF.PK) and Novo Nordisk A/S (NVO) announced Tuesday a translational drug discovery accelerator called LAB eN, which aims to nurture early research from academic institutions into novel therapeutics.
LAB eN is a unique engagement model that combines Evotec's multimodality drug discovery and pre-clinical development capabilities with Novo Nordisk's therapeutic, clinical, and commercial expertise.
LAB eN will focus on addressing unmet need in cardiometabolic diseases as well as rare blood and rare endocrine disorders.
LAB eN has already signed on four academic institutions to participate: Harvard University, Mass General Brigham, Yale University, and Beth Israel Deaconess Medical Center.
read more
Novo Nordisk Stock Climbs On Higher Q1 Results; Cuts FY25 Outlook
Shares of Novo Nordisk A/S were gaining around 6 percent in Denmark as well as around 7 percent in the pre-market activity on the NYSE, after the Danish drug major reported Wednesday higher profit and sales in its first quarter, mainly reflecting improved results of its blockbuster weight loss drug Wegovy. Meanwhile, the company trimmed fiscal 2025 outlook for sales and operating profit growth...
RTTNews
|
il y a 7
Novo Nordisk Plans $4.1 Bln NC Facility To Boost Obesity Drug Supply
Danish drug maker Novo Nordisk announced its plans to invest $4.1 billion or about 27 billion Danish kroner to build a new manufacturing plant in Clayton, North Carolina with a view to expanding its manufacturing capacity in the United States. In the new plant, the company plans to produce current and future injectable treatments for people with obesity and other serious chronic diseases.
RTTNews
|
il y a 324
Novo Nordisk Says FLOW Trial Achieves Primary Endpoint
Novo Nordisk A/S (NVO) announced Tuesday the headline results from the kidney outcomes trial FLOW. The announcement follows the decision to stop the trial early due to efficacy.
RTTNews
|
il y a 435
Novo Nordisk Slashes US List Prices Of Several Insulin Products By Up To 75%
Healthcare company Novo Nordisk Inc. (NVO) announced Tuesday it is lowering the U.S. list prices of several pre-filled insulin pens and vials by up to 75% for people living with type 1 and type 2 diabetes.
RTTNews
|
il y a 792
European Economic News Preview: UK GDP & Foreign Trade Data Due
First quarterly GDP estimates and foreign trade from the UK and flash GDP and employment from the euro area are the major reports due on Thursday. At 2.00 am ET, the Office for National Statistics publishes UK GDP, industrial output and foreign trade figures. The economy is expected to remain flat on month in March after expanding 0.5 percent in February.
RTTNews
|
il y a 21 minutes
Australian Market Turns To Modest Gains In Mid-market
The Australian market is turning its early losses to modest gains in mid-market on Thursday, after being in the red most of the morning session, extending the gains in the previous six sessions, following the mixed cues from Wall Street overnight. The benchmark S&P/ASX 200 is staying below the 8,300 level, with gains in financial and technology stocks nearly offset by weakness in mining stocks.
RTTNews
|
il y a 1h 43min
Indian Market Likely To Open On Cautious Note
Subdued GIFT Nifty, weak Asian stocks and the overnight mixed close on Wall Street point to a slightly negative start for Indian shares Thursday morning.
Investors are likely to react to a slew of quarterly earnings announcements.
RTTNews
|
il y a 1h 49min
Asian Markets Mixed Amid Cautious Trades
Asian stock markets are trading mixed on Thursday, following the mixed cues from Wall Street overnight, as traders remain cautious amid continued uncertainty surrounding US President Donald Trump's trade policies, despite reaching trade deals between the U.S. and China as well as the U.S. and the U.K. Asian Markets closed mostly higher on Wednesday.
RTTNews
|
il y a 1h 53min
